IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ21A

In re Application of:

M. EISENBACH-SCHWARTZ et al

Art Unit: 1649

Appln. No.: 10/807,414

Examiner: D. E. Kolker

Washington, D.C.

For: POLY-GLU, TYR FOR

NEUROPROTECTIVE THERAPY

Art Unit: 1649

Washington, D.C.

October 31, 2006

DECLARATION OF ESTER YOLES UNDER 37 CFR \$1.132

We, the undersigned Ester Yoles (also known as Eti Yoles) and Michal Schwartz (also known as Michal Eisenbach-Schwartz), hereby declare and state as follows.

We are the same Ester Yoles and Michal Eisenbach-Schwartz who are co-inventors, along with Ehud Hauben, on the above-identified patent application.

I, the undersigned Ester Yoles, am Vice President for Product Research and Development at Proneuron Biotechnologies, Weizmann Science Park, 74101 Ness-Ziona, Israel (hereinafter, Proneuron). My Curriculum Vitae is attached hereto as Exhibit A.

I, the undersigned Michal Schwartz, am a professor in the Department of Neurobiology at the Weizmann Institute of Science in Rehovot, Israel. My Curriculum Vitae is attached hereto as Exhibit B.

We are co-authors, among others, on a manuscript that has been submitted to, and recently accepted by, *Stroke*, a journal of the American Heart Association, entitled "A novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis," a copy of which is submitted herewith as Exhibit C.

All of the work described in Exhibit A was conducted either at Proneuron or in the laboratory of Prof. Michal Schwartz. Animal exposure to ischemic stroke and treatment with Poly-Glu, Tyr was done at Proneuron by or under the direct supervision of the undersigned Ester Yoles. All of the morphological measurements and data analysis was done in Prof. Schwartz' laboratory at the Weizmann Institute, by or under the direct supervision of the undersigned Michal Schwartz.

We hereby declare and state that all of the experimentation and results described in the attached manuscript was conducted by or under the direct supervision of one or the other of us and, accordingly, between the two of us, we can state of our firsthand knowledge that all of this description and the results set forth therein are true and correct to the best of our knowledge and belief.

Each of the undersigned declares further that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made

are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

31. oct. o6	Ester Yoles, Ph.D.
Date	Prof Michal Schwartz

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	Atty	7. Docket:	EIS-SCHWARTZ21A
In re Application of:)	Conf. No.:	3865
M. EISENBACH-SCHWARTZ et al)	Art Unit:	1649
Appln. No.: 10/807,414	<i>)</i>	Examiner:	D. E. Kolker
Filed: March 24, 2004)	Washington	, D.C.
For: POLY-GLU, TYR FOR NEUROPROTECTIVE THERAPY)	October 31	, 2006

DECLARATION OF ESTER YOLES UNDER 37 CFR §1.132

We, the undersigned Ester Yoles (also known as Eti Yoles) and Michal Schwartz (also known as Michal Eisenbach-Schwartz), hereby declare and state as follows.

We are the same Ester Yoles and Michal Eisenbach-Schwartz who are co-inventors, along with Ehud Hauben, on the above-identified patent application.

I, the undersigned Ester Yoles, am Vice President for Product Research and Development at Proneuron Biotechnologies, Weizmann Science Park, 74101 Ness-Ziona, Israel (hereinafter, Proneuron). My Curriculum Vitae is attached hereto as Exhibit A.

I, the undersigned Michal Schwartz, am a professor in the Department of Neurobiology at the Weizmann Institute of Science in Rehovot, Israel. My Curriculum Vitae is attached hereto as Exhibit B.

We are co-authors, among others, on a manuscript that has been submitted to, and recently accepted by, Stroke, a journal of the American Heart Association, entitled "A novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis," a copy of which is submitted herewith as Exhibit C.

All of the work described in Exhibit A was conducted either at Proneuron or in the laboratory of Prof. Michal Schwartz. Animal exposure to ischemic stroke and treatment with Poly-Glu, Tyr was done at Proneuron by or under the direct supervision of the undersigned Ester Yoles. All of the morphological measurements and data analysis was done in Prof. Schwartz' laboratory at the Weizmann Institute, by or under the direct supervision of the undersigned Michal Schwartz.

We hereby declare and state that all of the experimentation and results described in the attached manuscript was conducted by or under the direct supervision of one or the other of us and, accordingly, between the two of us, we can state of our firsthand knowledge that all of this description and the results set forth therein are true and correct to the best of our knowledge and belief.

Each of the undersigned declares further that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made

are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date		

Ester Yoles, Ph.D.

31/10/06

Date

Prof. Michal Schwartz